tbuckley/cabot-search huggingface dataset:
Table of Contents
Authors: Brad Rovin, Yosuke Hirakawa, Masaomi Nangaku, Vivekanand Jha, Adeera Levin, Yoshiki Higashijima, John Kellum, Mitra Nadim, Lui Forni, Germaine Wong, Toby Coates, Haikuo Li, Benjamin Humphreys, Dapa-Ckd Masaomi, Olivia Lenoir, Pierre-Louis Tharaux, Edward Clark, Greg Knoll, Michelle Rheault, Caroline Hsu, Daniel Weiner, P Coates, Jolanta Małyszko, Aristotelis Bamias, Farhad Danesh, Alicja Debska-Slizie, Maurizio Gallieni, Morie Gertz, Jan Kielstein, Petra Tesarova, Michael Cheung, David Wheeler, Wolfgang Winkelmayer, Camillo Porta, Chao Yang, Bixia Gao, Xinju Zhao, Zaiming Su, Xiaoyu Sun, Huai-Yu Wang, Ping Zhang, Rong Wang, Jian Liu, Wen Tang, Dongliang Zhang, Hong Chu, Jinwei Wang, Fang Wang, Song Wang, Li Zuo, Yue Wang, Feng Yu, Haibo Wang, Luxia Zhang, Hong Zhang, Li Yang, Jianghua Chen, Ming-Hui Zhao, John Søfteland, Kristjan Karason, Jesper Magnusson, Andreas Schult, Marie Felldin, Vanda Friman, Mihai Oltean, Marc Hazzan, Sophie Caillard, Nuri Baris Hasbal, Rimda Wanchoo, Maria Louise Barilla-Labarca, Kenar Jhaveri
Journal: Kidney International (2020)
Methyldopa-induced decrease in mental activity
Authors: S. Adler
Journal: JAMA (1974)

Five professional people, including three physicians, an engineer, and an accountant, reported severe changes in mental acuity, including lack of concentrating ability, amnesia-like episodes, difficulty in simple calculations, and problems in reading. Each was taking methyldopa at normal dosages, and when treatment with this drug was discontinued the mental symptoms disappeared within 96 hours. These cases emphasize the importance of questioning patients taking methyldopa about difficulties in mentation. (<i>JAMA</i>230:1428-1429, 1974)
Case mix classification: the need to reduce inappropriate homogeneity
Authors: J. S. Gonnella
Journal: JAMA (1986)

Accommodating different and divergent interests is not an easy task. Utilizing classification systems that fail to meet basic medical concepts, in terms of which disease and illness are understood, makes this task even more difficult. This can be seen in the article by Drs Iezzoni and Moskowitz<sup>1</sup>in this issue ofThe Journal. The goal of any classification system is to ensure that homogeneity is inherent in each category classified. An optimal classification system allows the prognosis and resource needs to be compared for individuals with "similar illnesses." The problem is the definition of "similar illness." Even though there may be biological similarities, there will be social differences that will affect patient care. Patient expectations and demands will also vary and will influence the effectiveness of the care given. Thus, case mix classification is an exercise in how best to pretend that what is in fact heterogeneous is homogeneous. The
Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics
Authors: Aziz Nazha, Vijaya R Bhatt, Graciela Nogueras-Gonzalez, Tapan Kadia, Jorge E. Cortes, Naval Daver, Guillermo Garcia-Manero, Hagop M. Kantarjian, Gautam Borthakur
Journal: Blood (2011)
Self-Rated Fair or Poor Health Among Adults With Diabetes—United States, 1996-2005
Journal: JAMA (2006)

Diabetes mellitus affects nearly 21 million persons in the United States. Maintaining and improving health-related quality of life among persons with diabetes is a public health goal. Healthy People 2010 includes self-rated health as one of three surveillance tools that can be used to measure health-related quality of life. To assess the prevalence of self-rated fair or poor health among U.S. adults with diabetes and to identify factors associated with fair or poor health, CDC analyzed 1996-2005 Behavioral Risk Factor Surveillance System (BRFSS) data. This report summarizes the findings of that analysis, which indicated that self-rated fair or poor health was three times more common among adults with diabetes than among those without diabetes and that the prevalence increased during 1996-2005 among young adults (i.e., aged 18-44 years) with diabetes. The results underscore the need for 1) continued interventions to promote healthy behaviors and prevent diabetes and 2) interventions for persons with diabetes to help them better manage their diabetes and prevent diabetes complications, which can increase their perceived quality of life.
Phase 1 study of LY317615 (enzastaurin) and temozolomide in patients with gliomas - EORTC trial 26054
Authors: R. Rampling, M. Sanson, W. Taal, C. Lai, C. Stoffregen, M. Munoz, T. Gorlia, A. Govaerts, D. Lacombe, M. Van den Bent
Journal: Journal of Clinical Oncology (2009)

e13005 Background: Enzastaurin (Enz) is a small selective inhibitor of protein kinase C (PKC). Synergy with temozolomide (TMZ) has been demonstrated in vitro. This phase I trial investigated optimal dosing and toxicity when Enz was combined with a standard TMZ regimen. Methods: Patients (pts) with recurrent high-grade glioma or newly diagnosed disease not amenable to radiotherapy (RT) and WHO PS 0–1 were eligible. Pts on EIAEDs were excluded. Two dose levels (DL) of Enz were explored. DL1: Loading dose 500 mg followed by 250 mg daily. DL2: Loading dose 1,125 mg followed by 500 mg daily. TMZ was given at 150 mg/m2 d1-d5 every 28 days in cycle 1, escalating to 200 mg/m2 in subsequent cycles. Dose-limiting toxicity (DLT) was defined by CTCAE 3.0 criteria in the first two cycles as (1) any non haematological toxicity grade 3/4 (2) ANC &lt; 500/mm3 (3) thrombocytopenia grade 3/4 (4) any toxicity reducing drug dose intensity to &lt;80%. Results: 15 pts were included, three at DL1, 12 at DL2. 13 pts had received prior RT, seven prior chemotherapy, and two were newly diagnosed. Median number of cycles was four (range 2–8).Treatment is ongoing in five pts. TMZ dose was escalated in all pts with no DLT. Modest and reversible thrombocytopenia was the most frequent toxicity, occurring in seven pts (3 @ Gd 1, 3 @ Gd2, 1 @ Gd 3) and led to TMZ dose reduction in two pts and treatment delays in four pts (multiple in 2). One pt discontinued after three cycles due to persistent thrombocytopenia. Five pts developed neutropenia not requiring dose modification. Two pts developed hyperbilirubinemia. Six SAE's (3 at each DL) were recorded, and one death (DL2). None was considered treatment related. Two pts showed a partial response, six pts stable disease. Conclusions: Enz can be safely combined with standard TMZ regimen. Results of the just completed phase I part with Enz 250 mg twice daily dosing will also be presented at the meeting. [Table: see text]
Correction of Defective Speech: A Complete Manual of Psycho-Physiological Technique for the Treatment and Correction of the Defects of Speech.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Successful Treatment of Naturally Occurring Influenza A/USSR/77 H1N1
Authors: Lee P. Van Voris
Journal: JAMA (1981)

Forty-five university students with proved influenza A/USSR/77 H1N1 infection were randomly treated with either amantadine hydrochloride (14 students), rimantadine hydrochloride (19 students), or placebo (12 students). By 48 hours after initiation of therapy, amantadine and rimantadine recipients had significantly less fever and greater improvement compared with subjects given the placebo. Minor reversible CNS side effects at the end of the five-day course of therapy were observed in one third of the amantadine-treated subjects. However, both amantadine and rimantadine recipients returned to classes earlier and shed smaller amounts of virus than placebo recipients. Thus, both drugs exerted a notable therapeutic effect. Hence, during an influenza outbreak, five days of empirical therapy with amantadine or rimantadine for persons with an influenza-like syndrome should ameliorate clinical symptoms and might decrease spread of virus. (<i>JAMA</i>1981;245:1128-1131)
The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease
Authors: S Takase
Journal: Hepatology (1993)

Progression of alcoholic liver disease is closely related to drinking habits. However, prognosis of alcoholic liver disease is not determined just by drinking habits, but also by other factors. In this study, the roles of alcohol-altered liver membrane antibody and hepatitis C virus infection were analyzed in alcoholic patients who were followed up for various lengths of time. Serial changes of liver histological appearance were analyzed in 39 patients with alcoholic liver disease who were followed for long periods (49.7 ± 34.3 mo) and who underwent liver biopsy at least two times. Prognoses of 35 patients with alcoholic cirrhosis who were followed for more than 1 yr were also evaluated. Development of cirrhosis in alcoholic liver disease was significantly higher in the alcohol-altered liver membrane antibody–positive patients than in the patients negative for this antibody. On the other hand, hepatitis C virus markers were not related to development of cirrhosis. However, hepatocellular carcinoma developed more frequently in the hepatitis C virus marker–positive patients. In patients with cirrhosis, the cumulative rates of hepatocellular carcinoma development were significantly higher in the hepatitis C virus marker–positive patients than in the marker-negative patients. Cumulative survival rates in the hepatitis C virus marker–positive patients were significantly lower than rates in the hepatitis C virus marker–negative patients, even in noncancer patients. However, such differences were not observed in the alcohol-altered liver membrane antibody–positive and alcohol-altered liver membrane antibody–negative cirrhotic patients. These results suggest that alcohol altered liver membrane antibody is a factor related to the progression of alcoholic liver disease and that hepatitis C virus infection is a determining factor for development of hepatocellular carcinoma and for prognosis of cirrhosis in patients who continue to drink. (HEPATOLOGY 1993;17:9–13.)
The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Students
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical News
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Implications for Human Health
Authors: Leon Golberg
Journal: Environmental Health Perspectives (1979)

To analyze the implications for human health, the toxicologist requires four sets of data: the results of toxicity and other studies in animals; quantitative data on actual or potential human exposure; whatever information is available on effects of exposure in man; and the statistical extrapolations from the dose-response relationships in animals to the (usually) much lower levels of human exposure. Professional expertise in toxicology is essential to assess the nature and severity of the toxic effects observed in animals, including such characteristics as potential for progression, irreversibility and production of incapacity. Given sufficient data, an estimate can be arrived at of the likelihood that such effects will be elicited in human populations of differing susceptibilities. The criteria by which the overall implications for human health can be judged comprise both the direct effects on man, as well as the indirect consequences stemming from environmental impacts.
Protein content of gastric juice: Part II In normal subjects and patients suffering from peptic ulcer and gastric carcinoma
Journal: Gut (1965)

and the presence of excess albumin loss into the gastro- intestinal tract in gastric carcinoma has been demonstrated by Jarnum and Schwartz (1960).Estimation of protein loss into the small and large intestine, due to problems of collection, will always involve complex procedures and depend upon assumptions that may not always be justified.However, gastric juice can be collected by continuous suction and the protein concentration estimated by conventional biochemical procedures.As no such study has been carried out, the present investigation was undertaken of the protein concentration and output in gastric juice in a series of control subjects and in patients suffering from gastric carcinoma, gastric ulcer, and duodenal ulcer, both under basal and stimulated conditions; gastric juice was collected by continuous suction and the protein concentration estimated using the biuret reaction.I 00 to m m i.
Medical licensure statistics for 1968
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rosamund Snow
Authors: David Payne
Journal: BMJ (2017)

On her first day as The BMJ's patient editor in 2014, Rosamund Snow disclosed that a favourite pastime of hers was watching classic episodes of Coronation Street.Early storylines in the long running ITV soap were a particular draw, she said, especially rows between Ena Sharples, the street's self-appointed moral guardian, and Elsie Tanner, the middle aged single mother looking for the elusive Mr Right.Snow admired Elsie's spirited struggles to gain understanding and respect, and her resilience in the face of censorious neighbours who lazily stereotyped her.
Las secreciones internas de las glándulas sexuales. El problema de la glándula de la pubertad.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Amer J of Roentgenology, Springfield, Ill
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum for the Research Article: “Sarcoplasmic reticulum calcium leak contributes to arrhythmia but not to heart failure progression” by B. A. Mohamed, N. Hartmann, P. Tirilomis, K. Sekeres, W. Li, S. Neef, C. Richter, E. M. Zeisberg, L. Kattner, M. Didié, K. Guan, J. D. Schmitto, S. E. Lehnart, S. Luther, N. Voigt, T. Seidler, S. Sossalla, G. Hasenfuss, K. Toischer
Journal: Science Translational Medicine (2019)
PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.
Authors: Isabelle Laure Ray-Coquard, Philipp Harter, Antonio Gonzalez Martin, Claire Cropet, Sandro Pignata, Keiichi Fujiwara, Christian Marth, Ignace Vergote, Mansoor Raza Mirza, Nicoletta Colombo, Per Rosenberg, Johanna Unelma Maenpaa, Eric Pujade Lauraine
Journal: Journal of Clinical Oncology (2017)

TPS5605 Background: Olaparib (Lynparza) is an oral PARP inhibitor indicated in the EU for the maintenance treatment of patients (pts) with platinum-sensitive relapsed BRCA-mutated high grade serous ovarian cancer (HGSOC). Bevacizumab is an anti-VEGF monoclonal antibody indicated in the EU in first line or relapse for the treatment of OC in combination with specific chemotherapeutic agents. Bevacizumab treatment is associated with increasing hypoxia-induced homologous recombination repair deficiencies in tumor cells, and is hypothesized to increase ovarian tumor sensitivity to olaparib. Methods: PAOLA-1 (ENGOT-ov25) is a randomized, placebo-controlled trial evaluating the efficacy and safety of olaparib (tablet formulation) in pts with advanced HGSOC receiving bevacizumab maintenance therapy. Eligible pts are those in complete or partial response following first-line platinum chemotherapy plus bevacizumab, and for whom bevacizumab maintenance therapy is planned. Approximately 762 European and 24 Japanese pts will be randomized 2:1 to olaparib 300 mg twice daily or placebo for up to 24 months. All pts will receive standard maintenance care of bevacizumab (15 mg/kg every three weeks) for up to 15 months. Primary objective: PFS1 according to RECIST 1.1 Secondary objectives: PFS2, OS, Safety, PRO/QoL, TFST, TSST All pts will undergo tumor BRCA testing prior to randomization. Central BRCA testing (tumor) will be performed in five screening platforms in France. Tumor BRCA test results have to be available within two months of sample provision. PFS will be evaluated using a log-rank test stratified by response to first-line treatment and BRCA mutation status. Treatment effect hazard ratio of 0.7 is expected and final PFS1 analysis will be performed after 372 events. The first pt from eight ENGOT groups plus Japan (10 participating countries) was randomized in July 2015. As of 31 January 2017, 549 pts have been randomized. The median period between the provision of a tumor sample and returned BRCA test result is 40 days. Accrual is expected to be complete before July 2017. Clinical trial information: NCT02477644.